Current Immunotherapeutic Strategies in Malignant Melanoma

Surgical Oncology Clinics of North America

Volumn 16, Issue 4, 2007, Pages 945-973

  Agostino, Nicole M ^a   Ali, Arjumand ^a   Nair, Suresh G ^a   Mosca, Paul J ^a  

^a LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOVECTIN 7; ANTINEOPLASTIC AGENT; CANCER VACCINE; CP 675206; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; HEAT SHOCK PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN; MELPHALAN; PF 33512676; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR STIMULATING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; INFECTION; INNATE IMMUNITY; LYMPH NODE METASTASIS; MELANOMA; NATURAL KILLER CELL; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA; MODELS, BIOLOGICAL;

EID: 36049047752     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.07.010     Document Type: Review

References (159)

1. Chong C.A., Gregor R.J., Augsburger J.J., et al. Spontaneous regression of choroidal melanoma over 8 years. Retina 9 2 (1989) 136-138
2. Shields C.L., Piccone M.R., Fung K.L., et al. Spontaneous regression of metastatic cutaneous melanoma to the choroid. Retina 22 6 (2002) 806-808
3. King M., Spooner D., and Rowlands D.C. Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: a case report and a review of the literature. Clin Oncol (R Coll Radiol) 13 6 (2001) 466-469
4. Morton D.L., Eilber F.R., Holmes E.C., et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180 4 (1974) 635-643
5. Darrow T.L., Slingluff Jr. C.L., and Seigler H.F. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 142 9 (1989) 3329-3335
6. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 5038 (1991) 1643-1647
7. Kawakami Y., Zakut R., Topalian S.L., et al. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 148 2 (1992) 638-643
8. Topalian S.L., Hom S.S., Kawakami Y., et al. Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J Immunother 12 3 (1992) 203-206
9. Hom S.S., Schwartzentruber D.J., Rosenberg S.A., et al. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother 13 1 (1993) 18-30
10. Storkus W.J., Zeh III H.J., Maeurer M.J., et al. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 151 7 (1993) 3719-3727
11. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10 3 (1999) 281-287
12. Chen Y.T., Scanlan M.J., Sahin U., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94 5 (1997) 1914-1918
13. Sahin U., Tureci O., Schmitt H., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92 25 (1995) 11810-11813
14. Cox A.L., Skipper J., Chen Y., et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264 5159 (1994) 716-719
15. Topalian S.L., Rivoltini L., Mancini M., et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91 20 (1994) 9461-9465
16. Parkhurst M.R., Fitzgerald E.B., Southwood S., et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58 21 (1998) 4895-4901
17. Spagnoli G.C., Adamina M., Bolli M., et al. Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. World J Surg 29 6 (2005) 692-699
18. Renkvist N., Castelli C., Robbins P.F., et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50 1 (2001) 3-15
19. Simpson A.J., Caballero O.L., Jungbluth A., et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5 8 (2005) 615-625
20. Epping M.T., and Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66 22 (2006) 10639-10642
21. Coley W.B. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus. Am J Med Sci 131 (1906) 375-430
22. Gallucci S., and Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 13 1 (2001) 114-119
23. Hsu L.C., Park J.M., Zhang K., et al. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428 6980 (2004) 341-345
24. Hattar K., Grandel U., Moeller A., et al. Lipoteichoic acid (LTA) from Staphylococcus aureus stimulates human neutrophil cytokine release by a CD14-dependent, Toll-like-receptor-independent mechanism: autocrine role of tumor necrosis factor-[alpha] in mediating LTA-induced interleukin-8 generation. Crit Care Med 34 3 (2006) 835-841
25. Haselmayer P., Tenzer S., Kwon B.S., et al. Herpes virus entry mediator synergizes with Toll-like receptor mediated neutrophil inflammatory responses. Immunology 119 3 (2006) 404-411
26. Pasare C., and Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438 7066 (2005) 364-368
27. Ruprecht C.R., and Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 36 4 (2006) 810-816
28. Peng G., Guo Z., Kiniwa Y., et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309 5739 (2005) 1380-1384
29. Chaperot L., Blum A., Manches O., et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176 1 (2006) 248-255
30. Horng T., Barton G.M., Flavell R.A., et al. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420 6913 (2002) 329-333
31. Hacker H., Redecke V., Blagoev B., et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439 7073 (2006) 204-207
32. Zhou X.-X., Jia W.-H., Shen G.-P., et al. Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev 15 5 (2006) 862-866
33. Kollisch G., Kalali B.N., Voelcker V., et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114 4 (2005) 531-541
34. Schaefer T.M., Fahey J.V., Wright J.A., et al. Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly (I:C). J Immunol 174 2 (2005) 992-1002
35. Beutler B., Hoebe K., Georgel P., et al. Genetic analysis of innate immunity: identification and function of the TIR adapter proteins. Adv Exp Med Biol 560 (2005) 29-39
36. Tsan M.F., and Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 76 3 (2004) 514-519
37. Lauzon N.M., Mian F., MacKenzie R., et al. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 241 2 (2006) 102-112
38. Sivori S., Falco M., Della Chiesa M., et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101 27 (2004) 10116-10121
39. Qian C., Jiang X., An H., et al. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood 108 7 (2006) 2307-2315
40. Delale T., Paquin A., Asselin-Paturel C., et al. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol 175 10 (2005) 6723-6732
41. Seigler H.F., Shingleton W.W., and Pickrell K.L. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; a clinical assessment. Plast Reconstr Surg 55 3 (1975) 294-298
42. Mastrangelo M.J., Bellet R.E., Berkelhammer J., et al. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36 4 (1975) 1305-1308
43. Baker M.A., and Taub R.N. BCG in malignant melanoma. Lancet 1 7812 (1973) 1117-1118
44. Nathanson L. Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Reports - Part 1 56 5 (1972) 659-665
45. Bluming A.Z., Vogel C.L., Ziegler J.L., et al. Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann Intern Med 76 3 (1972) 405-411
46. Mastrangelo M.J., Sulit H.L., Prehn L.M., et al. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 37 2 (1976) 684-692
47. Ariyan S., Kirkwood J.M., Mitchell M.S., et al. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery 92 3 (1982) 459-463
48. Livingston P.O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145 (1995) 147-166
49. Kolmel K.F., Grange J.M., Krone B., et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. A European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 41 1 (2005) 118-125
50. Agarwala S.S., Neuberg D., Park Y., et al. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100 8 (2004) 1692-1698
51. Krug A., Towarowski A., Britsch S., et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31 10 (2001) 3026-3037
52. Rao R.D., Anderson P.M., Arndt C.A., et al. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol 26 5 (2003) 493-498
53. Lee J.H., Torisu-Itakara H., Cochran A.J., et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11 1 (2005) 107-112
54. Nasi M.L., Lieberman P., Busam K.J., et al. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther 5 3 (1999) 139-144
55. Si Z., Hersey P., and Coates A.S. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6 3 (1996) 247-255
56. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 7 (1999) 2105-2116
57. Tarhini A.A., and Agarwala S.S. Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs 6 12 (2005) 1234-1239
58. Rosenberg S.A., Yang J.C., Topalian S.L., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 12 (1994) 907-913
59. Atkins M.B., Kunkel L., Sznol M., et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6 Suppl 1 (2000) S11-S14
60. Rosenberg S.A., and White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19 1 (1996) 81-84
61. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 14 (2003) 8372-8377
62. Morse M.A. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther 7 6 (2005) 588-597
63. Ribas A., Camacho L.H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23 35 (2005) 8968-8977
64. Pfeffer L.M., Dinarello C.A., Herberman R.B., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58 12 (1998) 2489-2499
65. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 11 (2006) 836-848
66. Morse M.A., Lyerly H.K., Clay T.M., et al. Immunotherapy of surgical malignancies. Curr Probl Surg 41 1 (2004) 15-132
67. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14 1 (1996) 7-17
68. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18 12 (2000) 2444-2458
69. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 9 (2001) 2370-2380
70. Kirkwood J.M., Ibrahim J., Lawson D.H., et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 19 5 (2001) 1430-1436
71. McMasters K.M. The Sunbelt Melanoma Trial. Ann Surg Oncol 8 9 Suppl (2001) 41S-43S
72. McMasters K.M., Noyes R.D., Reintgen D.S., et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 86 4 (2004) 212-223
73. Scoggins C.R., Ross M.I., Reintgen D.S., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24 18 (2006) 2849-2857
74. Gogas H., Bafaloukos D., Ioannovich J., et al. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year-a Hellenic Cooperative Oncology Group study. Anticancer Res 24 3b (2004) 1947-1952
75. Menon C., Iyer M., Prabakaran I., et al. TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model. Am J Physiol Heart Circ Physiol 284 1 (2003) H317-H329
76. Cornett W.R., McCall L.M., Petersen R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J Clin Oncol 24 25 (2006) 4196-4201
77. Hayes A.J., Neuhaus S.J., Clark M.A., et al. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 14 1 (2007) 230-238
78. Grunhagen D.J., de Wilt J.H., van Geel A.N., et al. Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol 32 4 (2006) 371-380
79. Grunhagen D.J., van Etten B., Brunstein F., et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 12 8 (2005) 609-615
80. Rossi C.R., Foletto M., Mocellin S., et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 11 2 (2004) 173-177
81. Bajetta E., Del Vecchio M., Mortarini R., et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4 1 (1998) 75-85
82. Gollob J.A., Veenstra K.G., Parker R.A., et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21 13 (2003) 2564-2573
83. Alatrash G., Hutson T.E., Molto L., et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22 14 (2004) 2891-2900
84. Lee P., Wang F., Kuniyoshi J., et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19 18 (2001) 3836-3847
85. Stagg J., Wu J.H., Bouganim N., et al. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 64 24 (2004) 8795-8799
86. Knutson K.L., Disis M.L., and Salazar L.G. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 56 3 (2007) 271-285
87. Nagai H., Horikawa T., Hara I., et al. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 13 10 (2004) 613-620
88. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200 6 (2004) 771-782
89. Jones E., Dahm-Vicker M., Simon A.K., et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity 2 (2002) 1-12
90. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 6 (2001) 823-832
91. Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 7 1 (2007) 11-17
92. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 33 1 Suppl 3 (2006) S11-S16
93. Attia P., Maker A.V., Haworth L.R., et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28 6 (2005) 582-592
94. Galanis E. Technology evaluation: Allovectin-7, Vical. Curr Opin Mol Ther 4 1 (2002) 80-87
95. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12 7 Pt 2 (2006) 2353s-2358s
96. Keilholz U. Biochemotherapy of melanoma. Forum (Genova) 13 2 (2003) 158-165 [quiz 189]
97. Alexandrescu D.T., Dutcher J.P., and Wiernik P.H. Metastatic melanoma: is biochemotherapy the future?. Med Oncol 22 2 (2005) 101-111
98. Buzaid A.C. Biochemotherapy for advanced melanoma. Crit Rev Oncol Hematol 44 1 (2002) 103-108
99. O'Day S.J., Kim C.J., and Reintgen D.S. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control 9 1 (2002) 31-38
100. Neri B., Vannozzi L., Fulignati C., et al. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a phase II study. Cancer Invest 24 5 (2006) 474-478
101. Lewis K.D., Robinson W.A., McCarter M., et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 24 19 (2006) 3157-3163
102. Ron I.G., Sarid D., Ryvo L., et al. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma Res 16 1 (2006) 65-69
103. Gonzalez Cao M., Puig S., Malvehy J., et al. Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial. Clin Transl Oncol Official Publ Fed Spanish Oncol Soc Natl Cancer Inst Mexico 7 6 (2005) 250-254
104. Hahka-Kemppinen M., Muhonen T., Virolainen M., et al. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol 132 6 (1995) 973-977
105. Vuoristo M.S., Grohn P., Kellokumpu-Lehtinen P., et al. Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 121 3 (1995) 175-180
106. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 8 (2002) 2045-2052
107. Lewis K.D., Gibbs P., O'Day S., et al. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest 23 4 (2005) 303-308
108. Krummel M.F., and Davis M.M. Dynamics of the immunological synapse: finding, establishing and solidifying a connection. Curr Opin Immunol 14 1 (2002) 66-74
109. Jansson A., Barnes E., Klenerman P., et al. A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol 175 3 (2005) 1575-1585
110. Ghiringhelli F., and Zitvogel L. Vaccine strategies against melanoma. Medecine Sciences (Paris) 22 2 (2006) 183-187
111. Kaplan J.M. New cancer vaccine approaches. Drugs of Today 40 11 (2004) 913-929
112. Mocellin S., Rossi C.R., and Nitti D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp Cell Res 299 2 (2004) 267-278
113. Dudley M.E., Ngo L.T., Westwood J., et al. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J 6 2 (2000) 69-77
114. Topalian S.L., Gonzales M.I., Parkhurst M., et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183 5 (1996) 1965-1971
115. Kobayashi H., Kokubo T., Sato K., et al. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 58 2 (1998) 296-301
116. Zarour H.M., Kirkwood J.M., Kierstead L.S., et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 97 1 (2000) 400-405
117. Manici S., Sturniolo T., Imro M.A., et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189 5 (1999) 871-876
118. Chaux P., Vantomme V., Stroobant V., et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189 5 (1999) 767-778
119. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 25 (2005) 6043-6053
120. Triozzi P.L., Aldrich W., Allen K.O., et al. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 28 4 (2005) 382-388
121. Jager E., Karbach J., Gnjatic S., et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103 39 (2006) 14453-14458
122. Flechtner J.B., Cohane K.P., Mehta S., et al. High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses. J Immunol 177 2 (2006) 1017-1027
123. Pilla L., Patuzzo R., Rivoltini L., et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 55 8 (2006) 958-968
124. Morton D.L., Hsueh E.C., Essner R., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236 4 (2002) 438-448
125. Morton DL. Multicenter double-blind phase 3 trial of Canvaxin vs placebo as post surgical adjuvant in metastatic melanoma. Paper presented at Society of Surgical Oncology 59th Annual Cancer Symposium. San Diego (CA), March 24, 2006.
126. Osada T., Clay T.M., Woo C.Y., et al. Dendritic cell-based immunotherapy. Int Rev Immunol 25 5-6 (2006) 377-413
127. Vilella R., Benitez D., Mila J., et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 53 7 (2004) 651-658
128. Salcedo M., Bercovici N., Taylor R., et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55 7 (2006) 819-829
129. Linette G.P., Zhang D., Hodi F.S., et al. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res 11 21 (2005) 7692-7699
130. Kyte J.A., Mu L., Aamdal S., et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13 10 (2006) 905-918
131. Grover A., Kim G.J., Lizee G., et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12 19 (2006) 5801-5808
132. Fay J.W., Palucka A.K., Paczesny S., et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 55 10 (2006) 1209-1218
133. Dillman R., Selvan S., Schiltz P., et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm 19 5 (2004) 658-665
134. Di Pucchio T., Pilla L., Capone I., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8 (+) T cells and monocyte/dendritic cell precursors. Cancer Res 66 9 (2006) 4943-4951
135. Banchereau J., Ueno H., Dhodapkar M., et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother 28 5 (2005) 505-516
136. Vujanovic L., Ranieri E., Gambotto A., et al. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther 13 8 (2006) 798-805
137. Krause S.W., Neumann C., Soruri A., et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25 5 (2002) 421-428
138. Wei Y., Sticca R.P., Holmes L.M., et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28 3 (2006) 585-593
139. Trefzer U., Herberth G., Wohlan K., et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23 17-18 (2005) 2367-2373
140. Neves A.R., Ensina L.F., Anselmo L.B., et al. Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother 54 1 (2005) 61-66
141. Trefzer U., Herberth G., Wohlan K., et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110 5 (2004) 730-740
142. Haenssle H.A., Krause S.W., Emmert S., et al. Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother 27 2 (2004) 147-155
143. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21 21 (2003) 4016-4026
144. Chiong B., Wong R., Lee P., et al. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma peptide vaccine. J Immunother 27 5 (2004) 368-379
145. Baselga J., Perez E.A., Pienkowski T., et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 Suppl 1 (2006) 4-12
146. Held G., Poschel V., and Pfreundschuh M. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 6 8 (2006) 1175-1186
147. Choi B.S., Sondel P.M., Hank J.A., et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother 55 7 (2006) 761-774
148. Grimm E.A., Ramsey K.M., Mazumder A., et al. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157 3 (1983) 884-897
149. Lindemann A., Herrmann F., Oster W., et al. Lymphokine activated killer cells. Blut 59 4 (1989) 375-384
150. Dudley M.E., Wunderlich J.R., Shelton T.E., et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26 4 (2003) 332-342
151. Ridolfi L., Ridolfi R., Riccobon A., et al. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. J Immunother 26 2 (2003) 156-162
152. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 10 (2005) 2346-2357
153. Johnson L.A., Heemskerk B., Powell Jr. D.J., et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177 9 (2006) 6548-6559
154. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 5796 (2006) 126-129
155. Ma Q., DeMarte L., Wang Y., et al. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther 11 4 (2004) 297-306
156. Ma Q., Safar M., Holmes E., et al. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 61 1 (2004) 12-25
157. Yun C.O., Nolan K.F., Beecham E.J., et al. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2 5 (2000) 449-459
158. Reinhold U., Liu L., Ludtke-Handjery H.C., et al. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J Investigative Dermatology 112 5 (1999) 744-750
159. Abken H., Hombach A., Heuser C., et al. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. Recent Results Cancer Res 158 (2001) 249-264